RIGEL PHARMACEUTICALS INC - 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by RIGEL PHARMACEUTICALS INC (RIGL) on March 10, 2025, covering events occurring on March 6, 2025. The filing reports the appointment of a new director to the Company's Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and director compensation arrangements.
Material Changes
The primary material change reported is the appointment of Mark J. Frohlich to the Board of Directors, effective March 6, 2025. Dr. Frohlich joins the class of directors with terms expiring at the 2027 annual stockholders' meeting and will serve on the Corporate Governance, Health Care Compliance Oversight and Nominating Committee and the Scientific and Clinical Trial Advisory Committee.
Compensation and Governance Details
- Cash Compensation: Dr. Frohlich receives a yearly retainer of $50,000, plus $10,000 annual retainers for each of his two committee assignments. Payments are pro-rated for partial periods.
- Equity Compensation: An initial option grant to purchase 12,000 shares of common stock was issued on the Effective Date. Future annual grants include options for 3,000 shares and 2,500 restricted stock units, contingent on continued service.
- Independence: The Board has determined Dr. Frohlich is independent under applicable SEC requirements and Nasdaq listing standards.
- Indemnification: A standard indemnification agreement has been executed with Dr. Frohlich.
Investor Verification Checklist
- Verify the independence status of Dr. Frohlich against the Company's Corporate Governance Guidelines.
- Review the terms of the 2018 Equity Incentive Plan regarding the vesting and exercise conditions of the 12,000 initial option shares.
- Confirm the total dilution impact of the initial grant and future annual equity awards on outstanding share counts.
- Check for any related party transactions or family relationships involving Dr. Frohlich, which the filing states do not exist.